Bedrijfsoverzicht
Liquidia Corporation is a biopharmaceutical entity dedicated to the development, manufacturing, and commercialization of therapeutic products designed for rare cardiopulmonary diseases within the United States market. Operating within the healthcare sector and specifically the drug manufacturers - specialty & generic industry, the company focuses on specialized pharmaceutical solutions that often target niche patient populations with unmet medical needs. The organization employs a workforce of 216 individuals and holds a market capitalization of $3.40 billion, reflecting significant investor interest despite its current profitability challenges. With an annual revenue of $158.32 million, these financial figures indicate that Liquidia has established a substantial commercial footprint and revenue generation capability relative to its small employee base, suggesting high operational leverage or a focus on high-value specialty products.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $158.32 million, yet this generated a net income of -$68,924,000 and an EBITDA of -$50,348,000, revealing a cost structure where expenses significantly outpace earnings before interest, taxes, depreciation, and amortization. This disparity between positive revenue and substantial negative net income highlights the heavy operational costs or research and development expenditures required to sustain the biopharmaceutical business model. Free cash flow stands at -$43,121,500, indicating that the company is currently burning cash rather than generating liquidity, which constrains financial flexibility and suggests a reliance on external capital sources or existing cash reserves to fund operations. Profitability is further analyzed through three distinct margins: a gross margin of 91.6% demonstrates highly efficient production costs relative to sales, while an operating margin of 21.5% shows that operating expenses consume a significant portion of that gross profit, ultimately resulting in a negative profit margin of -43.5%. The balance sheet presents a leveraged position with total debt of $197.93 million against total cash holdings of $190.68 million, and a debt-to-equity ratio of 442.31, indicating that the company is heavily reliant on equity financing or has substantial outstanding liabilities compared to shareholder equity. Despite the debt load, the current ratio of 2.01 suggests adequate short-term liquidity, as current assets are more than twice the value of current liabilities, providing a buffer for meeting immediate obligations. Return on Equity is recorded at -111.1% and Return on Assets at -11.5%, metrics that reveal management has not yet achieved positive returns on shareholder investments or the asset base, reflecting the transitional nature of the business as it navigates toward commercialization.
Waarderingsbeoordeling
Valuation metrics for Liquidia show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is 7.36, implying that the market expects earnings to turn positive in the future to justify the current price. The price-to-book ratio stands at 75.15, indicating that the market prices the company at a significant premium over its book value, likely reflecting the high value placed on its intellectual property and future product potential rather than current assets. Alternative valuation measures include a price-to-sales ratio of 21.46 and an EV/EBITDA of -67.61, which suggest that investors are valuing the company based on revenue multiples and enterprise value despite current losses, a common practice in early-stage biopharmaceutical development. The stock has traded within a 52-week range bounded by a high of $46.67 and a low of $11.85, meaning the current valuation sits somewhere within this historical volatility band and reflects market sentiment regarding its clinical progress. The beta value of 0.46 indicates that the stock exhibits lower price volatility relative to the broader market, moving less than half as much as the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is reported at an extraordinary 3054.6%, while earnings growth is N/A due to the company's current loss position, indicating that top-line expansion is occurring faster than profitability, a typical pattern during the scaling phase of biopharmaceutical commercialization. As a non-dividend payer, Liquidia does not distribute a dividend yield or maintain a payout ratio, as the company reinvests all available capital back into research, development, and market expansion rather than returning cash to shareholders. The absence of a payout ratio of 0.0% confirms that the firm prioritizes funding its pipeline and operational scaling over income distribution to investors. Overall, the growth and income profile is characterized by rapid revenue expansion coupled with significant cash consumption and no current income generation, highlighting a strategy focused entirely on achieving future commercial milestones rather than delivering immediate financial returns.